Medicines Co. Stock
-
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
Cons
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -0.250% | -4.075% | 11.207% | 0.743% | 1.751% | -20.349% | -8.247% |
| Opko Health Inc. | 1.170% | 2.292% | -6.313% | -22.272% | -20.302% | -18.675% | -71.164% |
| Amicus Therapeutics Inc. | -1.200% | -3.509% | 5.096% | -10.326% | -9.836% | -28.123% | -57.254% |
Comments
News
Meet the Biotech Stock That Just Jumped 251% Higher
Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can
Royalty Pharma (RPRX) Q2 Receipts Up 20%
Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its
BeOne Medicines (ONC) Q2 EPS Soars 924%
BeOne Medicines (NASDAQ:ONC), a global oncology-focused pharmaceutical company, released results for Q2 2025 on August 6, 2025. The most notable news was a sustained acceleration across revenue


